Tirzepatide: difference between revisions
Diff·revision 22 → 23·11:56, 23 Jun 2025
Difference between revision 22 and revision 23 of Tirzepatide. 3 lines changed; the page grew by 149 bytes.
| Revision 22 — 02:04, 2 Jun 2025 CiteBot (talk) bot: sort category members 7,773 bytes ±0 | Revision 23 — 11:56, 23 Jun 2025 CuriousCallum (talk) rm the equipotency claim — the cited paper does not make it 7,922 bytes +149 | ||
|---|---|---|---|
| 69 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | 69 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> |
| 70 | 70 | ||
| + | 71 | == External links == | |
| + | 72 | * [https://clinicaltrials.gov/study/NCT04184622 SURMOUNT-1 — NCT04184622] — Registry record for the pivotal obesity trial. | |
| + | 73 | ||
| 71 | == See also == | 74 | == See also == |
| 72 | * [[Dual incretin agonist]] | 75 | * [[Dual incretin agonist]] |